Varenicline tartrate

About Varenicline Tartrate (CAS 375815-87-5)

Varenicline tartrate (CAS 375815-87-5), also known as PF-03430574, is a selective nicotinic acetylcholine receptor partial agonist widely used in pharmacological and neurobiological research. The compound is primarily studied for its interaction with the α4β2 nicotinic acetylcholine receptor subtype, which plays a critical role in nicotine dependence and reward signaling pathways. Researchers frequently examine the varenicline tartrate structure to better understand receptor binding processes and to support the development of more effective therapeutic approaches for nicotine addiction and related neurological disorders. The compound is defined by a precise molecular formula, high chemical purity, and stable physicochemical characteristics, which make it appropriate for experimental research and screening applications. Laboratories involved in pharmaceutical development, academic pharmacology, and biotechnology often buy varenicline tartrate as a reference compound for receptor studies, ligand-binding assays, and mechanistic investigations. High-quality sourcing is essential, and researchers may buy 375815-87-5 from trusted suppliers to ensure consistent experimental outcomes and reproducible results.

Application Varenicline tartrate

Varenicline tartrate is primarily used in research focused on nicotine addiction mechanisms and cholinergic signaling pathways. Its pharmacological profile makes it a valuable compound for investigating receptor modulation, behavioral pharmacology, and therapeutic intervention strategies.

• Nicotine dependence research and receptor pharmacology
• Screening assays for nicotinic acetylcholine receptor modulators
• Drug discovery programs targeting addiction and neurological disorders
• Mechanistic studies of ligand-receptor interactions

Due to its defined receptor selectivity, the compound is frequently used as a reference standard in studies exploring new ligands targeting nicotinic receptors.

In Vitro

In vitro experiments demonstrate that varenicline tartrate acts as a partial agonist at α4β2 nicotinic acetylcholine receptors while showing weaker activity at other receptor subtypes. This partial activation helps modulate dopaminergic signaling pathways associated with nicotine reinforcement. Cell-based assays and receptor binding experiments often utilize varenicline tartrate to evaluate the potency and selectivity of newly synthesized compounds targeting cholinergic receptors.

Researchers studying receptor pharmacodynamics also use the compound to characterize ligand-binding kinetics and intracellular signaling responses. Because the varenicline tartrate structure has been extensively characterized, it provides a reliable model compound for validating assay systems.

In Vivo

In vivo studies show that varenicline tartrate influences dopamine release within brain reward circuits by partially stimulating nicotinic receptors. Animal models of nicotine dependence have demonstrated that the compound reduces nicotine-seeking behavior and withdrawal symptoms. These properties have made it an important reference compound in addiction research.

Preclinical investigations frequently include PF-03430574 to assess behavioral outcomes, evaluate receptor selectivity in complex biological systems, and validate therapeutic strategies targeting cholinergic pathways.

Biochem/physiol Actions

The biochemical activity of varenicline tartrate is based on its ability to bind selectively to neuronal nicotinic acetylcholine receptors. As a partial agonist, it provides moderate receptor activation while simultaneously preventing full stimulation by nicotine. This dual mechanism modulates neurotransmitter release and reduces reinforcement signaling.

From a physiological perspective, the compound influences dopamine release in mesolimbic pathways, which are associated with reward processing and addiction-related behaviors. These effects make it particularly valuable in research examining the neurochemical mechanisms underlying nicotine dependence.

Features and Benefits Varenicline tartrate

Researchers choose varenicline tartrate for several reasons related to reliability, reproducibility, and pharmacological relevance. Its well-studied receptor profile makes it a dependable tool for neuropharmacology and drug discovery programs.

• Selective partial agonist of α4β2 nicotinic acetylcholine receptors
• Widely validated compound in addiction and neurobiology research
• Suitable for both in vitro and in vivo pharmacological studies
• Consistent chemical quality for reproducible screening results

Scientific teams often perform supplier comparisons before purchasing research molecules. Many laboratories searching for reliable sources may look for options such as varenicline tartrate buy from specialized chemical providers with established quality control standards. As noted in the project brief, research organizations value access to high-quality bioactive compounds supported by reliable scientific documentation and availability for discovery programs.

Complete Stock Solution Preparation Table

Preparation of stock solutions depends on the experimental design and solvent compatibility. Varenicline tartrate is commonly dissolved in aqueous buffers or compatible laboratory solvents to achieve the required working concentrations. Accurate preparation ensures consistent dosing across assays and experimental models.

When preparing stock solutions, researchers should consider factors such as compound solubility, storage stability, and experimental concentration ranges. Proper preparation and storage help maintain the integrity of the compound and ensure reliable pharmacological results during screening and mechanistic studies.